MGI(SH:688114) Xin Lang Cai Jing·2026-02-03 11:57Core Viewpoint - The company Huada Zhi Zao (688114) has announced a plan to acquire "San Jian Qi Fa" and "Hua Da Xu Feng" for 366 million yuan, aiming to integrate spatial omics and nanopore sequencing technologies, positioning itself as the only life science company globally with a complete product matrix of "long-read sequencing + spatial omics" [1][7]. Group 1: Nanopore Sequencing Business - The Cyclone SEQ series has shown significant market expansion since its launch in September 2024, with a diverse customer base including universities, research institutes, and hospitals, and has successfully entered overseas markets in Asia-Pacific and Latin America [1][7]. - The nanopore sequencing business is expected to grow due to market space and synergy effects, with a projected global compound annual growth rate of approximately 22% for long-read sequencing [2][8]. - The company plans to enhance its market competitiveness through channel integration and cost optimization, leveraging its established global sales network and reducing unit costs via large-scale production [2][8]. Group 2: Spatial Omics Business - The spatial omics technology has accumulated over 200 clients, with about half from industrial sectors and the rest from academic and research institutions, indicating a high customer repurchase rate that reflects its practical value [3][9]. - The company has implemented a differentiated global strategy for spatial omics, focusing on local service capabilities in China, targeting top academic institutions in the Americas, and establishing a balanced cooperation network in Europe [4][10]. - The core competitive advantage of spatial omics lies in its ability to achieve high resolution and large field of view, addressing industry challenges and providing critical support for detailed research in tumor microenvironments and cellular interactions [5][11]. Group 3: Future Growth Directions - The company aims to expand its application boundaries in the research field, exploring potential uses in neuroscience, brain-machine interfaces, embryonic development, agricultural breeding, and forensic testing [6][12]. - In the clinical field, the company is collaborating with global pharmaceutical companies and hospital experts to advance digital spatial pathology analysis, fostering rapid implementation and industrial application of this leading technology [6][12]. - The company plans to enhance customer engagement by offering bundled solutions that integrate nanopore technology with single-cell sequencing and spatial omics, optimizing pricing strategies to attract a broader user base [3][9].